TP53 and central nervous system cancer: Finally, we tested whether there is a difference in the P1-, P2- or P1/P2 ratio of MDM2 mRNA among high-grade (GBs) vs lower-grade gliomas (AAs and As) with no MDM2 gene amplification and wild-type TP53 and p14ARF genes.